Trial · NCT06956885
Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout
NCT06956885, Phase 2, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout. Trials, record NCT06956885. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06956885
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout
- NCT number
- NCT06956885
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 450 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Gout Chronic
- Interventions
- Discontibuation of oral ULT, Maintenance of ULT
- First posted
- 2025-05-04
- Last updated
- 2025-05-04
Source ClinicalTrials.gov
Registered outcomes77
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients experiencing one or more flares | At 2 years | According to the Gaffo's criteria |
| Secondary | Proportion of patients experiencing one or more flares | At 6 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Proportion of patients experiencing one or more flares | At 12 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Proportion of patients experiencing one or more flares | At 18 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Proportion of patients experiencing one or more flares | At 30 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Proportion of patients experiencing one or more flares | At 36 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Mean flare rates | At 6 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Mean flare rates | At 12 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Mean flare rates | At 18 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
| Secondary | Mean flare rates | At 24 months | According to both the Gaffo's criteria and the patient-reported Gout Attack Intensity Score (GAIS) |
1 to 10 of 77Source ClinicalTrials.gov
See all 77 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06956885
GET https://conductscience.org/api/trials/v1/NCT06956885/registered?page=2